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Abstract
The availability of erythropoiesis-stimulating agents
(ESAs) has revolutionized the treatment of anaemia in pa-
tients with chronic kidney disease. However, maintaining
patients at haemoglobin (Hb) levels that are both safe and
provide maximal benefit is a continuing challenge in the
field. Based on emerging data on the potential risks of Hb
treatment targets >13 g/dL, treatment targets have recently
been lowered. In the latest revision (March 2008) of the
European product labelling for the ESA class of drugs, the
target treatment range was lowered to 10–12 g/dL. Fluc-
tuation of Hb levels or ‘Hb variability’ during treatment
with ESAs is a well-documented phenomenon. Hb levels
that are either too high or too low may have an adverse ef-
fect on patient outcomes; thus, it is important to understand
the causes of Hb variability in order to achieve optimal
treatment. Several factors are believed to contribute to vari-
ation in the Hb level, including patient comorbidities and
intercurrent events. Inflammation is also an important fac-
tor associated with Hb variability, and the consequences
of persistent inflammatory activity are far-reaching in af-
fected patients. This review addresses the complex role of
inflammation in chronic kidney disease, as evidenced by
the apparent state of deranged inflammatory markers. The
mechanisms by which inflammatory cytokines may affect
theresponsetoESAs,thedevelopmentofanaemiaandpoor
treatment outcomes are also examined. In addition, various
options for intervention to enhance the response to ESAs in
haemodialysis patients with inflammation are considered.
Keywords: anaemia management; chronic kidney
disease; epoetin hyporesponsiveness; haemoglobin
variability; inflammation
Introduction
Anaemia management with erythropoiesis-stimulating
agents(ESAs)isanimportantaspectofcareforhaemodial-
ysis (HD) patients because anaemia is one of the common
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consequences of chronic kidney disease (CKD). The Eu-
ropean Best Practice Guidelines (EBPG) for the manage-
ment of anaemia of CKD specified that, within the recom-
mended target range (at the time >11 g/dL, not exceeding
12–14 g/dL), the exact patient target haemoglobin (Hb)
level should be defined on an individual basis, taking into
account gender, age, ethnicity, activity and comorbid con-
ditions [1]. The importance of setting an upper limit for
target Hb concentration was highlighted through the pub-
lication of results from the CREATE [2] and CHOIR [3]
studies and a large meta-analysis [4]. Although the recom-
mended target range has just been lowered to 10–12 g/dL
as a result of the above study results [5,6], an individual
patient’s demographic and disease characteristics, as well
as cormorbidities, continue to be an important considera-
tion in determining target Hb. In HD patients, for example,
higher Hb concentrations are particularly undesirable due
to risks arising from post-dialysis haemoconcentration [7].
Haemoglobin variability
Attheindividualpatientlevel,Hbconcentrationsfrequently
exhibit a cyclical pattern over time such that a substantial
proportion of dialysis patients receiving ESAs experience
Hb levels both above and below the target range during
a relatively short period of follow-up [8,9]. In the Dialysis
OutcomesandPracticePatternsStudy(DOPPS),aprospec-
tiveobservationalstudythatanalysedanaemiamanagement
and outcomes in long-term HD patients from 12 countries,
83–94% of patients were receiving treatment with an ESA
yet only 23–77% of patients in respective countries had a
Hb concentration <11 g/dL [10]. Similarly, Lacson et al.
[8] reported that few patients maintained Hb in the target
range in a study that measured variability in Hb level over
1 year in a large cohort of patients with end-stage renal dis-
ease(ESRD).Overall,only38.4%ofpatientshadHblevels
between 11 and 12 g/dL, while 12.2%, 31.5% and 30% of
patients had Hb levels <10 g/dL, <11 g/dL and >12 g/dL,
respectively. Of note, at the time of these studies, the EBPG
recommended treating patients until Hb reached >11 g/dL
with an upper limit of 12–14 g/dL [1].
While mean Hb levels may appear stable over time in
any given population of dialysis patients, few individual
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Fig. 1. Factors associated with Hb variability. Hb, haemoglobin; sHPT,
secondary hyperparathyroidism; PRCA, pure red cell aplasia; RBC, red
blood cell.
patients maintain stable Hb. Ebben et al. [9] measured Hb
levels in a large cohort of patients for 6 months and found
that the percentage of patients who were below, within and
above the target range (defined as 11–12.5 g/dL at the time
of study conduct) remained stable. However, this stability
was not evident from individual data, as only a minority of
patients (6.5%) had stable Hb levels over the study period,
with nearly 90% exhibiting some pattern of Hb fluctua-
tion [9,11]. A wide variety of factors have been associated
with Hb variability, including patient factors, comorbidi-
ties, intercurrent events and practice procedures (Figure 1)
[9,12–21]. This review will mainly address the impact of
persistent inflammation on both Hb variability and respon-
siveness to ESAs in the treatment of anaemia of CKD.
However, another intercurrent event worthy of mention is
neocytolysis, thephysiological processbywhichyoung cir-
culating erythrocytes (neocytes) are selectively destroyed
when red cell mass becomes excessive [15]. Evidence sug-
gests that a greater understanding of this process may also
help to optimize the treatment of these patients.
Clinical consequences of haemoglobin variability
Recent studies have suggested an association of Hb vari-
ability with mortality, while other studies suggest that low
Hb levels may be the critical factor associated with poor
outcomes. In retrospective analyses of 34 963 HD patients,
Yang et al. [22] and Brunelli et al. [23] found that a greater
Hb variability was associated with diminished survival.
However,theassociationwasnotevidentinthesubgroupof
patients with Hb ≥10.5 g/dL, though this might have been
due to the smaller size of this subgroup. Ebben et al.[ 9 ] ,
in a much larger retrospective study of 152 846 patients,
characterized six different types of Hb variability patterns
and then evaluated hospitalizations and comorbidities in
these categories. They observed that the group of patients
with consistently low Hb levels had the highest percent-
age of hospitalizations and the highest number of comorbid
conditions [9]. In a similar sample of 159 720 HD patients
receiving epoetin, Gilbertson et al. found that the longer
HD patients had a Hb level <11 g/dL, the greater their
mortality risk (P < 0.001) [11]. In another large retrospec-
tive study of HD patients, the proportion of time spent with
Fig. 2. Hb levels and risk for mortality and hospitalization in the Dial-
ysis Outcomes and Practice Patterns Study (DOPPS). Hb, haemoglobin.
Reprinted from [10], Copyright (2004), with permission from Elsevier.
Hb levels below a target of 11 g/dL was compared against
the risk of death [24]. The results showed a clear trend of
increased mortality with increasing time below this target
level. For patients with Hb levels <11 g/dL for 80–100% of
thetime,theriskwas∼1.8timesashighasforpatientswith
no time below this level. This trend was also observed in
theDOPPS, wherehigher Hbvaluesatthestartofthestudy
among patients on dialysis therapy for longer than 180 days
wereassociatedwithalowerriskformortalityandhospital-
ization (Figure 2) [10]. These data suggest that maintaining
patients within the target Hb range is an important goal in
the treatment of renal anaemia.
Computerized anaemia management to reduce
haemoglobin variability
Given the importance of Hb stability in renal anaemia man-
agement, it is necessary to continue to both assess and
refine target Hb ranges and to develop possible system-
atic processes for deciding how much and when to adjust
doses of ESAs. In the last few years, considerable advances
have been made in this area through computer-assisted
implementation of treatment algorithms based on practice
guidelines.
One such anaemia management system is known as the
Leeds Algorithm, developed in Leeds, UK. Patient data,
such as ESA and iron supplement doses, Hb levels, serum
ferritin and iron status, are extracted from local hospital
computerized patient records. Using these data, the Leeds
Algorithm programme then provides recommendations for
changesinESAandirondose,asappropriate,fromananal-
ysis against pre-determined thresholds. Richardson et al.
[25] explored the consequences of setting different thresh-
olds and ceilings for epoetin dose changes in two random-
ized, controlled studies in unselected HD patients. In one
study, the dose of epoetin was increased when Hb levelsi20 A. L. M. de Francisco et al.
fell below either 10.5 g/dL or 11.5 g/dL in 236 patients fol-
lowed up for 6 months. In the other study, the dose of epo-
etin was reduced at Hb levels above either 12 g/dL or 13 g/
dL in 211 patients followed up for 8 months. Using this
management system, a narrowing of the Hb level distribu-
tion could be achieved. Thus, the study demonstrated that
the formal use of threshold and ceiling values for interven-
tion using the Leeds Algorithm enabled the production of
pre-specified Hb outcome distributions from the HD popu-
lation. Gaweda et al. [26] also developed an algorithm, for
model predictive control (MPC), using an artificial neural
network model of Hb response to ESA treatment. Results
showed that MPC of ESA administration may lead to an
improvement in anaemia management.
Haemoglobin variability as a consequence
of inflammation
Evidence suggests that inflammation is an important fac-
tor associated with Hb variability and that high C-reactive
protein (CRP) levels (a widely used surrogate marker of
inflammatory activity) are a predictor for less stable Hb
control in CKD patients. This was shown by Dellanna et al.
[27] who analysed data from 225 HD patients in a retro-
spective, single-centre, 1-year longitudinal cohort study to
determine risk factors associated with less stable Hb con-
trolinresponsetoESAtreatment.Inpatientswith<60%of
meanmonthlyHblevels>11g/dL,CRPvalueswerehigher
(P < 0.0001) than in patients with 61–100% of monthly Hb
levels >11 g/dL (Table 1). No significant differences were
found between iron and dialysis parameters. Mueller et al.
[28] conducted a study of similar design over 6 months in
1573 HD patients to determine patterns of Hb variability
and contributing factors. As in the study by Dellanna et al.
[27], lower average CRP values were associated with bet-
ter Hb control (P<0.0001), and no significant differences
regarding ferritin, transferrin saturation or dialysis param-
eters were found (the authors concluded that CRP was the
only causal factor of Hb variability that they could ob-
serve) [28]. In a third study, Agarwal et al. [29] showed
that S-albumin (another inflammatory marker) is also an
important predictor of baseline Hb and sensitivity to ESAs.
Barany et al. [30] also sought to identify factors
associated with Hb variability in prevalent HD patients.
Table 1. Association of Hb variability (expressed as percentage of mean
monthly values >11 g/dL over 1 year) with CRP levels and epoetin dose
in 225 haemodialysis patients [27]
Time Hb >11 g/dL (%) n (%) CRP (mg/dL) Epoetin dose
(IU/week)
81–100 120 (53.3) 1.3 5966
61–80 54 (24.0) 2.2 7510
41–60 34 (15.1) 2.7 10 163
21–40 12 (5.3) 2.9 10 947
0–20 5 (2.2) 2.4 13 357
Total 225 (100) 1.8 7407
CRP, C-reactive protein; Hb, haemoglobin; IU, international units.
Copyright 2006 by American Society of Nephrology. Reproduced with
permission of American Society of Nephrology via Copyright Clearance
Center.
High-sensitivity CRP levels were recorded weekly, and
Hb, interleukin-6 (IL-6), ferritin and percentage of
hypochromicredcells(HRC)wererecordedmonthlyin228
patients during 3 months of follow-up. For each patient,
the median and range values during the study were used
for analysis. Two groups were formed whereby either all
measurements of Hb levels were above the target value of
11 g/dL (n=104) or at least one measurement was below
the target value (n=124). While comorbidity had no di-
rect influence on Hb levels, significant correlations were
found between Hb variation and CRP variation (P<0.05)
and between HRC variation (P<0.001) and ferritin vari-
ation (P<0.01). HRC variation also correlated with IL-6
variation (P<0.001) and CRP variation (P < 0.001). The
associations between inflammatory markers and iron pa-
rameters in this study also suggested that inflammation
had indirect effects on Hb variability via effects on iron
metabolism.
Consequences of inflammation on mortality
It has been recognized that more than 30–50% of patients
with ESRD have serological evidence of an activated in-
flammatory response, as shown by increased levels of CRP
and pro-inflammatory cytokines, such as IL-1, IL-6 and
tumour necrosis factor (TNF-α) [31–35]. These height-
ened levels of inflammatory markers are associated with
reduced survival in these patients. This was demonstrated
by Kalantar-Zadeh et al. [36] who measured serum lev-
els of myeloperoxidase (MPO), an enzyme that is released
during inflammation, at the start of a 3-year study in 356
patients undergoing maintenance HD. The adjusted hazard
ratio for death for each 1000 pmol/L increase in MPO level
was found to be 1.14 [95% confidence interval (CI) 1.03–
1.26, P = 0.01]. After dividing MPO values into tertiles,
the hazard ratio for death of the highest tertile (versus the
middle tertile) was 1.82% (95% CI 1.07–3.10, P = 0.03).
The link between MPO and inflammation was confirmed
by the positive correlation between MPO and serum CRP
values.
In the Modification of Diet in Renal Disease (MDRD)
study, CRP was measured at baseline in 697 stage 3 and
4 CKD patients to examine the relationship of CRP lev-
els (stratified into high CRP ≥0.3 mg/dL versus low CRP
<0.3 mg/dL) with cause of death [37]. High CRP was
found to be an independent predictor of both all-cause mor-
tality and cardiovascular mortality. Zimmermann et al. [38]
and Qureshi et al. [39] were the first to show that overall
mortality and cardiovascular mortality were significantly
higher in patients with elevated CRP levels compared with
thoseexhibitingnormalCRPlevels(P<0.0001)whenthey
monitored outcome over a year in 280 HD patients. When
Stenvinkel et al. [33] examined IL-6 levels in incident dial-
ysis patients, they observed that elevated levels were sig-
nificantlyassociatedwithpooroutcome.Whenpatientdata
weredividedintoquartilesaccordingtobasallevelsofIL-6,
the survival rate was shown to be statistically different be-
tweenquartiles(P<0.00001).Thus,alinkbetweeninflam-
mation and a higher risk of mortality has been established
in numerous studies.Consequences of inflammation in chronic kidney disease i21
Fig. 3. Relationship between inflammatory cytokines and response to
epoetin.IL,interleukin;rh-EPO,recombinanthumanerythropoietin;TNF-
α, tumour necrosis factor-α. Reprinted from [40] by permission from
Macmillan Publishers Ltd.
Consequences of inflammation on response
to ESAs
A proportion of patients treated with ESAs respond poorly
or not at all, and in a subset of these, no obvious cause
(suchasirondeficiency)canbefound.Severalstudieshave
suggested that failure to respond to ESAs in CKD patients
is due to enhanced immune activation that might suppress
erythroid precursor cell production.
The interactions between different inflammatory medi-
ators and ESA response appear to be complex. Further-
more, the patterns of cytokines and their interactions may
be more important than individual circulatory plasma lev-
els. In a study of 34 HD patients, Goicoechea et al. [40]
found evidence for a relationship between deranged cy-
tokine production and therequired dose of epoetin. Epoetin
responsiveness was linked to the levels of IL-6, TNF-α and
IL-12. Patients with levels of TNF-α ≥2 ng/mL and IL-6
≥40 ng/mL required a significantly higher dose of epo-
etin than patients with lower levels of these cytokines (128
U/kg/week versus 57 U/kg/week; P = 0.0024) (Figure 3).
Significant positive correlations between IL-6 and TNF-α
production values and epoetin doses were observed (P =
0.039 and P = 0.02, respectively). Conversely, there was a
negative correlation between IL-12 production values and
epoetin doses (P = 0.029). Two other early studies showed
a correlation between high levels of CRP and increased re-
sistance to erythropoietin in HD patients [41,42]. Barany
et al. [41] found that the weekly dose of epoetin in patients
with a serum CRP level ≥2 mg/dL was on average 80%
higher than the dose in patients whose serum CRP level
was <2 mg/dL.
Another study investigated cross-sectional associations
between inflammatory markers and the required dose of
epoetin among 339 maintenance HD outpatients within
a 13-week interval [43]. Serum concentrations of high-
sensitivity CRP, IL-6 and TNF-α were observed to have
a positive correlation with the required epoetin dose and
with an index of epoetin responsiveness (average weekly
epoetin dose divided by the average blood Hb level).
In an Italian multicentre study, Locatelli et al. [44] ex-
amined the relationship between the natural logarithm of
the weekly epoetin dose, normalized for post-dialysis body
weight and outcome measures of nutrition or inflamma-
tion in 677 HD patients. Patients were categorized into four
groups (untreated, hyperresponders, normoresponders and
hyporesponders) on the basis of weekly epoetin dose re-
quirement. Multiple linear regression analysis showed that
CRP, Hb and serum iron levels were independently associ-
ated with the natural logarithm of the weekly epoetin dose.
Median CRP level was higher in the hyporesponders than
in the other groups (1.9 versus 0.8 mg/dL; P = 0.004). The
median weekly epoetin dose ranged from 30 IU/kg/week in
thehyperresponsivegroupto263IU/kg/weekinthehypore-
sponsive group. Ferritin levels were lower in the hypore-
sponders than in other patients (median 318 versus 445 ng/
mL; P = 0.01). Taken together, these findings support a
clear association between epoetin hyporesponsiveness and
either increased levels of CRP or iron deficiency in HD
patients.
Furtherstudieshaveshownthatchangesininflammatory
status contribute to both hyporesponsiveness to epoetin and
variability of Hb levels in CKD patients. This was shown
in a 6-month analysis (already described) of data from
1573 HD patients in a study conducted by Mueller et al.
[28]. In addition to lower average CRP values, the patients
withbettercontrolledHblevels(61–100%ofmeanmonthly
Hb values >11 g/dL) had lower average epoetin doses than
the patients with poorly controlled Hb levels (0–60% of
mean monthly Hb values >11 g/dL) [28].
Inaddition,asignificantdifferencebetweenepoetindose
(P<0.0001) and CRP level (P<0.0001) was observed in
patients with a Hb change within 3 months of ≥2g / d L
versus <2 g/dL. Another recent study demonstrated the
presence of the IL-6 polymorphism -174G, a genotype as-
sociated with increased secretion of IL-6, resulting in a
requirement for higher doses of ESAs [45].
Potential anaemic effects of pro-inflammatory
cytokines
One link between elevated levels of pro-inflammatory cy-
tokines and poor treatment outcomes in CKD patients may
be the presence of anaemia. Evidence suggests several
mechanisms by which inflammatory cytokines may affect
the development of anaemia.
Suppression of bone marrow erythropoiesis
Many investigators have shown, using in vivo and in vitro
studies, that cytokines can suppress erythroid progenitor
cell proliferation. For example, IL-1 was shown to antag-
onize the capacity of epoetin to stimulate the proliferation
of bone marrow erythroid precursors in culture [46], while
serum from patients with both ESRD and inflammatory
disease inhibited erythroid colony formation and response
to epoetin, a process that was restored by the addition ofi22 A. L. M. de Francisco et al.
antibodies to TNF-α and interferon (IFN)-α [47]. Some
studies, however, have failed to show a cytokine-mediated
suppressionofprogenitorcellproliferation.Innormalmice,
for example, daily injections of IL-6 produced an increase
in the number of progenitor cells in bone marrow [48]. In
addition, other cytokines such as IL-12 have been shown
in vitro to stimulate the growth of murine erythroid bone
marrow progenitor cells [49].
Suppression of erythropoietin production
Erythropoietin levels in anaemic patients with chronic dis-
orders, such as cancer, may be inappropriately low for
the degree of anaemia, suggesting that erythropoietin de-
ficiency may contribute to the development of this form
of anaemia [50]. IL-1α,I L - 1 β and TNF-α were shown to
inhibit erythropoietin production in cultures of human hep-
atoma cell lines [51], and to cause dose-dependent inhi-
bition of hypoxia-induced erythropoietin production in the
cell line Hep3b [52]. Another study showed, however, that
the epoetin response did not differ between rats with both
acute inflammation and anaemia and control animals with
a comparable degree of anaemia [53].
Increased intestinal bleeding
IL-6,whenadministeredintraperitoneallytorats,wasfound
to be associated with blood loss in intestinal tissue us-
ing erythrocyte labelling with 99mtechnetium, as well as a
markeddecreaseinHblevels[54].Inthisstudy,noevidence
was found for suppression of bone marrow erythropoiesis.
Modulation of iron metabolism
Anaemia of inflammation is characterized by decreased
iron and iron-binding capacity (transferrin), increased fer-
ritinandthepresenceofironinbonemarrowmacrophages,
indicating impaired mobilization of iron from stores. In
general, cytokines may impair iron metabolism, leading
to functional iron deficiency, via several different mecha-
nisms. First, high doses of ESAs may overstimulate ery-
thropoiesis to exceed the maximum capacity of liver iron
stores. Secondly, increased ferritin and decreased transfer-
rin production shunt iron to the reticulo-endothelial storage
pool, preventing delivery to erythroid precursors. In addi-
tion, mucosal uptake and mucosal transfer of iron have
been shown to be significantly reduced in HD patients
with increased CRP levels (>8 mg/L versus <8m g / L ,
P<0.01) [55]. Patients with increased CRP levels had sig-
nificantly higher serum ferritin concentration (P<0.02),
lower serum transferrin concentrations (P<0.01) and re-
quired higher epoetin doses to maintain a stable haema-
tocrit between 30% and 35% (P<0.05), confirming the
pattern of functional iron deficiency in the anaemia of
inflammation.
Recently, hepcidin, the hormone responsible for iron
homeostasis, has emerged as a key mediator responsi-
ble for the disturbed iron metabolism in the anaemia of
CKD [56]. Synthesized in the liver, hepcidin acts by con-
trolling intestinal iron uptake and retention of iron in
macrophages engaged in the recycling of iron from senes-
cent erythrocytes. Specifically, hepcidin has been shown
to bind to ferroportin, a transmembrane protein that is the
sole known cellular exporter of iron. After binding, ferro-
portinisinternalizedanddegraded,leadingtothedecreased
export of iron and cellular iron retention [57,58]. Thus,
the hepcidin–ferroportin interaction determines serum iron
concentrations.
Hepcidin expression is regulated in response to various
stimuli. Synthesis of hepcidin increases in response to iron
overload[59]anddecreasesinresponsetoanaemia,hypoxia
and erythropoiesis [60,61]. Hepcidin expression is also up-
regulated during infections and inflammation, contribut-
ing to hypoferraemia and limitation of iron supply to the
bone marrow (independent of iron status or erythropoietic
activity) [56]. The IL-6 inflammatory cytokine, released
during the inflammatory process, was shown to correlate
with dramatically increased hepcidin gene expression both
in mice and humans [62]. In patients with renal insuffi-
ciency (likely due to the low-grade inflammation in these
patients),elevatedlevelsofboththehepcidinprecursorpro-
hepcidin[63–65]andhepcidin[66]havebeendetected,and
have been hypothesized to be responsible for the iron defi-
ciency and anaemia seen in these patients. Thus, hepcidin
may link inflammation and anaemia, acting as an indicator
of functional iron deficiency [56,60,67]. The contribution
of hepcidin to the aetiology of resistance to ESA therapy
remains to be established.
The available evidence suggests that CKD is a state of
increased pro-inflammatory cytokine activity that might
suppress erythroid progenitor cell production leading to
hyporesponsiveness to ESAs and poor treatment out-
comes. Understanding the influence of inflammatory
cytokines on erythropoietin production will hopefully pro-
vide clarification of the complex interplay between mul-
tiple factors involved in the pathogenesis of the anaemia
of CKD. Possible future pharmacological interventions for
inflammation-associated hyporesponsiveness to ESA treat-
ment include anti-cytokine and anti-oxidative treatment
strategies.
Interventions for ESRD patients with
inflammation
A number of possible strategies exist to enhance the re-
sponse to ESAs and iron in ESRD patients with persistent
low-grade inflammation. Despite the high prevalence of
chronic inflammation in CKD, some basic tenets regard-
ing the treatment of inflammation are obvious and apply to
all patients regardless of whether or not they are on dialy-
sis. Occult infections, when found, should be treated with
antibiotics. Also, occult infection of old, non-functioning,
arteriovenous grafts (AVGs) is a common cause of ESA
resistance and a chronic inflammatory state in HD patients.
Resection of old non-functioning AVGs with occult infec-
tionisassociatedwiththeresolutionofmarkersofachronic
inflammatory state and improvement in responsiveness to
ESA treatment [68]. Optimal treatment of chronic heart
failure is essential as it may cause, or contribute to, an
inflammatory state [69]. Chronic heart failure with fluidConsequences of inflammation in chronic kidney disease i23
overload, a common feature in dialysis patients, may be an
important cause of inflammation. Thus, rigorous measures
should be taken to avoid or treat fluid overload in these
patients [31].
Optimization of the dialysis procedure
The available evidence suggests that the HD procedure it-
self may cause an inflammatory response and that using
biocompatiblemembranes[70]andultrapuredialysate[71]
canreducesucharesponse.Asnewandmorebiocompatible
peritoneal dialysis solutions become available, they should
beconsideredinperitonealdialysispatientswithsignsofin-
flammation. In addition, evidence suggests that the dialysis
schedule may have an impact on the levels of inflammatory
markers.Ayusetal.[72]showed,inanon-randomizedclin-
ical trial, that compared with conventional HD (three 4-h
sessions per week), short daily dialysis (six 3-h sessions
per week) was associated with a reduction in the levels of
inflammatory markers and left ventricular hypertrophy.
In a recent study, patients receiving on-line haemofiltra-
tion,whichremovesawidespectrumofuraemictoxins,ex-
hibited micro-inflammation to a lesser degree than patients
on high-flux HD [73]. On-line haemofiltration combines
convective transport, for the removal of large solutes, with
diffusion, for the removal of small solutes. The study also
demonstrated a correlation between increased inflamma-
tion and induction of endothelial damage in HD patients.
Thus, optimizing the dialysis procedure may be important
to decrease the prevalence of inflammation in HD patients.
Immune modulation
Pentoxifylline, a drug traditionally used in the treatment of
peripheralvasculardiseasebecauseofitspotenthaemorrhe-
ological properties, was found to have anti-inflammatory
properties in vitro. From this observation, Cooper et al.
[74] hypothesized that pentoxifylline might improve the
response to ESAs in anaemic CKD patients by inhibiting
pro-inflammatorycytokineproductioninvivotogiveriseto
enhanced erythropoiesis. A total of 12 patients with ESRD
and ESA-resistant anaemia completed treatment with oral
pentoxifylline for 4 months. At the end of the treatment
period, the mean Hb concentration significantly increased
(P = 0.0001), ex vivo T-cell expression of TNF-α signifi-
cantlydecreased(P=0.0007)(Figure4)andIFN-γexpres-
sion decreased (P = 0.0002) from baseline levels. Thus,
pentoxifylline therapy had significantly improved the Hb
responseinpatientswithpreviouslyESA-resistantanaemia
in renal failure. The authors concluded that this might have
occurred due to inhibition of pro-inflammatory cytokine
production, which could interfere with the effectiveness of
ESA treatment.
Anti-oxidant treatment
As oxidation products may promote persistent inflamma-
tion in uraemia, the use of anti-oxidants, such as vitamin E,
Fig. 4. Correlation between change in TNF-α and Hb in patients treated
with pentoxifylline [74]. Hb, haemoglobin; TNF-α, tumour necrosis
factor-α.
which can modulate cytokine biology, is of particular inter-
est. Indeed, vitamin E supplementation improved the thera-
peutic effect of ESA treatment in children with CKD [75].
In this study, the efficacy of combined therapy with epo-
etin and vitamin E versus epoetin alone in the treatment of
anaemia was examined in 10 children on chronic HD. Vita-
minEwasintroducedafter2weeksofepoetinmonotherapy,
when the signs of acute oxidative stress appeared. After 2
weeks of vitamin E treatment, there was a considerable de-
crease in indices of oxidative stress compared with epoetin
monotherapy. A significant increase in Hb and haematocrit
(P < 0.01) was achieved within 2 weeks of starting the
combinedtherapy,whilesimilarresultsoccurredonlyatthe
fifth and eighth weeks without vitamin E. In another study,
HD using vitamin E-modified dialysis membranes in ESA-
treated patients also improved anaemia, and this appeared
to be a direct consequence of the concentration-dependent
effect of plasma vitamin E in improving red blood cell sur-
vival [76]. As present data in the literature are based on
small patient cohorts, larger prospective randomized trials
will be needed to determine whether anti-oxidative treat-
ment strategies are beneficial to the anaemic CKD patient
with inflammation.
Resection of failed kidney transplants
It has been common practice not to remove failed kidney
transplants. However, evidence now suggests that the pres-
ence of a failed kidney transplant in HD patients may be as-
sociatedwithachronicinflammatorystate.Thisinturncan
result in resistance to ESAs. In a study by Lopez-Gomez
et al. [77], resection of failed kidney transplants led to a
significant decrease in levels of inflammatory markers.
Conclusion
Persistent inflammation may contribute to the variability
in Hb levels and hyporesponsiveness often seen in CKD
patients. This variability, or perhaps more specifically,
Hb variability in which Hb values are often below target
range, may be associated with increased morbidity andi24 A. L. M. de Francisco et al.
mortality in these patients. Recently developed comput-
erized anaemia management systems may offer one op-
portunity to control Hb concentrations within the target
range, providing physicians with a basis to treat patients in
an objective and systematic manner. These computerized
systems are likely to grow in importance and benefit, and
shouldleadtobetterandsimplerpatientmanagementinthe
future.
The available evidence suggests that CKD is a state of
increased pro-inflammatory cytokine activity, which might
suppresserythroidprogenitorcellproductionleadingtohy-
poresponsiveness to ESAs and poor treatment outcomes.
Understanding the influence of inflammatory cytokines
on erythropoietin production and hepcidin synthesis will
hopefully clarify the interplay of the multiple factors in-
volved in the pathogenesis of the anaemia of chronic
disease. Possible future pharmacological interventions for
inflammation-associated hyporesponsiveness to ESA ther-
apy include anti-cytokine and anti-oxidative treatment
strategies.
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